3 related results for VKA


NOACs confer lower bleeding risk than VKA in low-risk AF patients

Literature 21-6-2017 • Lip GYH et al., JAMA Cardiol. 2017
In AF patients with a single non-gender-related stroke risk factor, the risk of any bleeding was lower for apixaban and dabigatran compared with warfarin, while no difference in stroke prevention was seen.

FORTA classifies all DOACs and warfarin as beneficial for older AF patients

Literature 17-5-2017 • Wehling M, et al, Drugs & Aging 2017
Based on FORTA classification, all DOACs and warfarin were classified as beneficial or very beneficial for older AF patients, while there was lack of evidence for other vitamin K antagonists.

Doubled risk of acute MI in real world AF patients receiving DOACs or aspirin vs. VKA

Literature 11-4-2017 • Stolk LM et al., Br J Clin P harmacol 2017
Analysis of new users of rivaroxaban or dabigatran, aspirin and VKAs in CPRD reveals a two-fold increased risk of AMI in current users of DOAC or aspirin, as compared with VKA.

Upcoming meetings

EPCCS Council Meeting December 6-7, 2017, Stratford Upon Avon, United Kingdom
10th EPCCS Annual CV Summit for Primary care March 15-16, 2018, Malaga, Spain
All upcoming meetings...

Meeting reports & resources

EPCCS 2017 Report of the Cardiovascular Summit held in Dublin, Ireland
EPCCS Guidance Documents Evidence- and meeting-based guidance for primary care
EPCCS 2015 Report of 8th Annual EPCCS meeting held in Prague.
EPCCS 2014 Report of 7th Annual EPCCS meeting held in Brussels.
All meeting reports...